natgillin/translations-raw huggingface dataset:
Table 1: Interactions between the individual components of Delstrigo and other medicinal products
Preglednica 1: Medsebojna delovanja posameznih sestavin zdravila Delstrigo in drugih zdravil
Doravirine has not been evaluated in patients with previous virologic failure to any other antiretroviral therapy.
Doravirina niso ocenili pri bolnikih s predhodnim virološkim neuspehom katerega koli drugega protiretrovirusnega zdravljenja.
Delstrigo Once Daily ISG
Zdravilo Delstrigo enkrat na dan ISG
• Periodic Safety Update Reports (PSURs)
• Redno posodobljena poročila o varnosti zdravila (PSUR)
The marketing authorization holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
Other reasons include: lost to follow-up, non-compliance with study drug, physician decision, protocol deviation, withdrawal by subject.
Drugi razlogi vključujejo: izgubljeni tekom spremljanja, nesodelovanje (nekomplianca) pri uporabi raziskovanega zdravila, zdravnikova odločitev, kršitev protokola, umik s strani preiskovanca.
*The 95 % CI for the treatment difference was calculated using stratum-adjusted Mantel-Haenszel method.
*95-odstotni interval zaupanja za razliko med zdravljenji je izračunan po Mantel-Haenszelovi metodi s prilagoditvijo za stratume.
Some patients required hospitalisation and renal replacement therapy.
Nekateri bolniki so potrebovali sprejem v bolnišnico in nadomestno zdravljenje ledvic.
Blood tests may also show: • increased levels in liver enzymes (ALT)
Preiskave krvi lahko pokažejo tudi: • zvišanje jetrnih encimov (ALT)
*For Week 96, certain subjects with missing HIV-1 RNA were excluded from the analysis.
*Pri analizi za 96. teden so bili določeni preiskovanci z manjkajočim HIV-1 RNA izkjučeni iz analize.
Women with HIV should not breastfeed because HIV can be passed on to babies through breast milk.
Ženske, okužene z virusom HIV, ne smejo dojiti, ker lahko virus z mlekom prenesejo na otroka.
Lamivudine has been identified in breast-fed newborns/infants of treated women.
Lamivudin so zaznali pri dojenih novorojenčkih/dojenčkih zdravljenih žensk.
Tell your doctor right away if you start having any new symptoms after starting your HIV medicine.
Zdravnika morate takoj obvestiti, če se vam po začetku jemanja zdravila proti virusu HIV pojavijo kakšni novi simptomi.
• Swallow the tablet whole (do not crush or chew).
• Tableto zaužijte celo (ne smete je drobiti ali žvečiti).
 = increase, ↓ = decrease, ↔ = no change CI = Confidence Interval; SD = Single Dose; QD = Once Daily; BID = Twice Daily *AUC0- for single dose, AUC0-24 for once daily.
 = povečanje, ↓ = zmanjšanje, ↔ = brez spremembe IZ = interval zaupanja, 1x/dan = enkrat na dan, 2x/dan = dvakrat na dan *AUC0- za enkratni odmerek, AUC0-24 za uporabo enkrat na dan
This can happen when you start taking any HIV medicine, including Delstrigo.
Ta se lahko pojavi, ko začnete jemati katero koli zdravilo proti virusu HIV, tudi zdravilo Delstrigo.
If you accidentally take more, contact your doctor.
Če pomotoma vzamete več zdravila, se posvetujte z zdravnikom.
A panel of 96 diverse clinical isolates containing NNRTI-associated mutations was evaluated for susceptibility to doravirine in the presence of 10 % foetal bovine serum.
Skupino 96 različnih kliničnih izolatov, ki so imeli z NNRTI povezane mutacije, so ovrednotili glede občutljivosti na doravirin v prisotnosti 10 % fetalnega govejega seruma.
In humans, the only known metabolite is the trans-sulphoxide metabolite (approximately 5 % of an oral dose after 12 hours).
Pri človeku je edini znani presnovek transsulfoksidni presnovek (približno 5 % peroralnega odmerka po 12 urah).
You should not take Delstrigo if your doctor has told you that the virus causing your infection is resistant to any of the medicines in Delstrigo.
Zdravila Delstrigo ne smete jemati, če vam je zdravnik povedal, da je virus, ki povzroča okužbo pri vas, odporen proti kateri koli učinkovini v zdravilu Delstrigo.
ombitasvir/paritaprevir/ ritonavir and dasabuvir +/ritonavir
ombitasvir/paritaprevir/ ritonavir in dasabuvir +/ritonavir
Successful genotype, n Genotypic resistance to DOR or control (DRV or EFV) 2 (DOR)
Genotipska odpornost proti DOR ali kontrola (DRV ali EFV) 2 (DOR)
In vitro studies have determined that neither tenofovir disoproxil nor tenofovir are substrates for the CYP450 enzymes.
Študije in vitro so pokazale, da niti dizoproksiltenofovirat niti tenofovir nista substrata encimov CYP450.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redkimi prirojenimi motnjami, kot so intoleranca za galaktozo, popolno pomanjkanje laktaze ali malabsorpcija glukoze-galaktoze, ne smejo jemati tega zdravila.
Very rare peripheral neuropathy (or paraesthesia)*
Zelo redki periferna nevropatija (ali parestezije)*
You can still pass on HIV when taking Delstrigo, although effective therapy lowers the risk.
Tudi med jemanjem zdravila Delstrigo lahko še vedno prenašate virus HIV, čeprav učinkovito zdravljenje zmanjša to tveganje.
EU/1/18/1333/001 EU/1/18/1333/002 90 (3 x 30) tablets
EU/1/18/1333/001 EU/1/18/1333/002 90 (3 x 30) tablet
Worsening of hepatitis B infection
Poslabšanje okužbe z virusom hepatitisa B
It is not considered to be causally associated with tenofovir disoproxil in the absence of this condition.
Ne ocenjujejo ga kot vzročno povezanega z dizoproksiltenofoviratom v odsotnosti te motnje.
Information regarding potential medicinal product interactions with other antiretroviral medicines is not provided.
Tukaj niso navedene informacije o možnih medsebojnih delovanjih zdravila z drugimi protiretrovirusnimi zdravili.
New onset or worsening renal impairment
Novonastala okvara ledvic ali poslabšanje okvare ledvic
This is because other medicines may affect how Delstrigo works, and Delstrigo might affect the way some other medicines work.
Druga zdravila namreč lahko vplivajo na delovanje zdravila Delstrigo pa tudi zdravilo Delstrigo lahko vpliva na delovanje nekaterih drugih zdravil.
Week 24 N=223
24. teden N = 223
Excretion of unchanged medicinal product via urinary excretion is minor.
Izločanje nespremenjenega zdravila z urinom je majhno.
Includes subjects who discontinued because of adverse event (AE) or death if this resulted in no virologic data on treatment during the specified window.
Vključuje preiskovance, ki so prenehali sodelovati zaradi neželenega učinka (NU) ali smrti, če je to povzročilo, da niso imeli viroloških podatkov med zdravljenjem v opredeljenem oknu.
No human data on the effect of Delstrigo on fertility are available.
Podatkov o vplivu zdravila Delstrigo na plodnost pri človeku ni.
• muscle weakness, weakening of the bones (with bone pain and sometimes resulting in fractures)
• oslabelost mišic, oslabitev kosti (z bolečinami v kosteh in včasih z zlomi)
The pharmacokinetics of lamivudine and tenofovir have not been studied in subjects older than 65 years.
Farmakokinetike lamivudina in tenofovirja niso raziskali pri osebah, starejših od 65 let.
Table 5: Efficacy response (Snapshot approach) in the DRIVE-SHIFT study
Preglednica 5: Odziv učinkovitosti (metoda "Snapshot") v študiji DRIVE-SHIFT
Week 48 and 96 outcomes for DRIVE-FORWARD and DRIVE-AHEAD are provided in Table 4.
Izidi v preskušanjih DRIVE-FORWARD in DRIVE-AHEAD 48. in 96. teden so prikazani v preglednici 4.
The use of Delstrigo in people aged less than 18 years has not yet been studied.
Uporaba zdravila Delstrigo pri osebah, mlajših od 18 let, še ni raziskana.
Discontinued study due to AE or Death
Prenehanje sodelovanja v študiji zaradi NU ali smrti
Tenofovir is excreted in human milk.
Tenofovir se izloča v materino mleko.
HIV is the virus that causes AIDS (‘acquired immune deficiency syndrome').
Virus HIV lahko povzroči aids (sindrom pridobljene imunske pomanjkljivosti).
• increased levels in liver enzymes (AST)
• zvišanje jetrnih encimov (AST)
There are no data available on the safety of lamivudine when administered to babies less than three months old.
Podatkov o varnosti lamivudina, uporabljenega pri dojenčkih, mlajših od treh mesecev, ni.
Delstrigo is used to treat HIV infection in people 18 years of age and older.
Zdravilo Delstrigo se uporablja za zdravljenje okužbe s HIV pri osebah, starih 18 let ali več.
Keep desiccant inside the bottle and do not throw away until you have finished taking all of the medicine.
Sušilo naj ostane v plastenki in se ga ne sme zavreči, dokler ne porabite vsega zdravila.
Lamivudine Lamivudine does not inhibit or induce CYP enzymes.
Lamivudin Lamivudin ne zavira in ne inducira encimov CYP.
The effects of tenofovir disoproxil associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown.
Učinki sprememb MKG in biokemičnih označevalcev, povezanih z dizoproksiltenofoviratom, na dolgoročno zdravje kosti in tveganje za prihodnje zlome niso znani.
Delstrigo contains lactose monohydrate.
Zdravilo Delstrigo vsebuje laktozo monohidrat.
Discuss your hepatitis B therapy with your doctor.
O zdravljenju hepatitisa B se posvetujte z zdravnikom.
NRTI backbone M184I/V only K65R only K65R + M184I/V
NRTI osnova samo M184I/V samo K65R K65R + M184I/V
Rare dyspnoea, tonsillar hypertrophy
Redki dispneja, hipertrofija tonzil
Doravirine at a dose of 100 mg once daily is not likely to have a clinically relevant effect on the plasma concentrations of medicinal products that are dependent on transport proteins for absorption and/or elimination or that are metabolised by CYP enzymes.
Ni verjetno, da bi doravirin v odmerku 100 mg enkrat na dan klinično pomembno vplival na plazemsko koncentracijo zdravil, ki so za absorpcijo in/ali odstranjevanje odvisna od transportnih beljakovin oziroma se presnavljajo z encimi CYP.
The adverse reactions with suspected (at least possible) relationship to treatment are listed below by body system organ class and frequency.
Neželeni učinki, domnevno (vsaj morda) povezani z zdravljenjem, so navedeni spodaj po organskih sistemih in pogostnosti.
The EC50 values for tenofovir were in the range of 0.04-8.5 microM.
Vrednosti EC50 tenofovirja so bile v razponu od 0,04 do 8,5 mikroM.
The highest frequency category reported in the 3TC or TDF Summary of Product Characteristics is used.
Uporabljena je najvišja kategorija pogostnosti, navedena v povzetku glavnih značilnosti zdravila za 3TC ali TDF.
No dose adjustment is required.
Odmerka ni treba prilagoditi.
• medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol,
• zdravila (običajno tekočine), ki vsebujejo sorbitol ali druge sladkorne alkohole (kot so ksilitol,
The muscle pain, muscle weakness and decreases in potassium or phosphate in the blood may occur due to damage to kidney tubule cells.
Bolečine v mišicah, šibkost mišic in znižanje kalija ali fosfata v krvi se lahko pojavijo zaradi okvare celic ledvičnih tubulov.
If bone abnormalities are suspected, then appropriate consultation should be obtained.
V primeru suma na kostne nepravilnosti je potrebno ustrezno posvetovanje.
During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.
Med uvodno fazo kombiniranega protiretrovirusnega zdravljenja se lahko pri bolnikih, katerih imunski sistem se odzove, razvije vnetni odziv na indolentne ali rezidualne oportunistične okužbe (kot so npr. okužba z Mycobacterium avium, z virusom citomegalije, pljučnica zaradi Pneumocystis jirovecii [PCP] ali tuberkuloza), zaradi katerih so lahko potrebne dodatne preiskave in zdravljenje.
A large amount of data on pregnant women (more than 3,000 outcomes from first trimester) taking the individual active component lamivudine in combination with other antiretrovirals indicates no malformative toxicity.
Obsežni podatki pri nosečnicah (več kot 3.000 izidov od prvega trimesečja), ki so jemale samostojno učinkovino lamivudin v kombinaciji z drugimi protiretrovirusnimi zdravili, ne kažejo malformacijskih toksičnih učinkov.
While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission of HIV-1, a residual risk cannot be excluded.
Dokazano je sicer, da učinkovita supresija virusov s protiretrovirusnim zdravljenjem bistveno zmanjša tveganje za spolni prenos HIV-1, vendar določenega preostalega tveganja ni mogoče izključiti.
In a population pharmacokinetic analysis, which included subjects with CrCl between 17 and 317 mL/min, renal function did not have a clinically relevant effect on doravirine pharmacokinetics.
V populacijski farmakokinetični analizi, ki je vključevala preiskovance z očistkom kreatinina med 17 in 317 ml/min, delovanje ledvic ni klinično pomembno vplivalo na farmakokinetiko doravirina.
EC50 values were in the range of 0.003 to 15 microM (1 microM = 0.23 micrograms per mL).
Vrednosti EC50 so bile v razponu od 0,003 do 15 mikroM (1 mikroM = 0,23 mikrograma na ml).
Patients who are co-infected with HIV-1 and HBV should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment with Delstrigo.
Bolnike, ki so sočasno okuženi s HIV-1 in HBV, je treba natančno klinično in laboratorijsko spremljati vsaj še nekaj mesecev po prenehanju zdravljenja z zdravilom Delstrigo.
If you have HIV infection and hepatitis B infection, it is especially important not to stop your Delstrigo treatment without talking to your doctor first.
Če ste okuženi s HIV in s hepatitisom B, je še posebej pomembno, da z zdravljenjem z zdravilom Delstrigo ne prenehate, ne da bi se prej posvetovali z zdravnikom.
Ribavirin (50 microM) used in the treatment of chronic HCV infection decreased the anti-HIV-1 activity of lamivudine by 3.5-fold in MT-4 cells.
Ribavirin (50 mikroM), uporabljen pri zdravljenju kronične okužbe s HCV, je v celicah MT-4 zmanjšal aktivnost lamivudina proti HIV-1 za 3,5-krat.
Lamivudine was not teratogenic in animal studies but there were indications of an increase in early embryonic deaths in rabbits at relatively low systemic exposures, comparable to those achieved in humans.
V študijah na živalih lamivudin ni bil teratogen, obstajali pa so znaki večjega števila zgodnjih smrti zarodkov pri kuncih ob razmeroma majhnih sistemskih izpostavljenostih, primerljivih tistim, ki so dosežene pri človeku.
Delstrigo is a complete regimen for the treatment of HIV-1 infection; therefore, Delstrigo should not be administered with other antiretroviral medicinal products.
Zdravilo Delstrigo je popolna shema za zdravljenje okužbe s HIV-1, zato se ga ne sme uporabljati z drugimi protiretrovirusnimi zdravili.
• if you are allergic to doravirine, lamivudine or tenofovir disoproxil or any of the other ingredients of this medicine listed in section 6.
• če ste alergični na doravirin, lamivudin, dizoproksiltenofovirat ali katero koli sestavino tega zdravila, navedeno v poglavju 6.
It is unknown whether doravirine is excreted in human milk.
Ni znano, ali se doravirin pri človeku izloča v materino mleko.
If appropriate, initiation of anti-hepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis, since post-treatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.
Če je primerno, je lahko potrebna uvedba zdravljenja proti hepatitisu B, zlasti pri bolnikih z napredovalo boleznijo jeter ali cirozo, kajti poslabšanje hepatitisa po zdravljenju lahko povzroči jetrno dekompenzacijo in odpoved jeter.
• This medicinal product does not require any special temperature storage conditions.
• Za shranjevanje zdravila niso potrebna posebna navodila glede temperature.
Week 48 N=447
48. teden N = 447
Doravirine 100 mg once daily
Doravirin 100 mg enkrat na dan
Studies with lamivudine show that plasma concentrations (AUC) are increased in patients with renal dysfunction due to decreased clearance.
Rezultati študije z lamivudinom kažejo, da se koncentracija v plazmi (AUC) pri bolnikih z motenim delovanjem ledvic zaradi manjšega očistka poveča.
Genotypic analysis showed that the resistance was due to a specific amino acid substitution in the HIV-1 RT at codon 184 changing the methionine to either isoleucine or valine (M184V/I).
Genotipska analiza je pokazala, da je bila odpornost posledica specifične aminokislinske substitucije v RT HIV-1 na kodonu 184 s spremembo metionina ali v izolevcin ali v valin (M184V/I)
Based on administration of an IV microdose, the volume of distribution of doravirine is 60.5 L. Doravirine is approximately 76 % bound to plasma proteins.
Na podlagi uporabe intravenskega mikroodmerka je volumen porazdelitve doravirina 60,5 l. Doravirin je približno v 76 % vezan na beljakovine v plazmi.
In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.
Pri nekaterih bolnikih z napredovalo boleznijo jeter ali cirozo prenehanje zdravljenja ni priporočljivo, ker lahko povzroči poslabšanje hepatitisa, to pa je lahko življenjsko nevarno.
Following oral administration, the terminal halflife of tenofovir is approximately 12 to 18 hours.
Terminalni razpolovni čas tenofovirja po peroralni uporabi je približno 12 do 18 ur.
Because of the potential for HIV-1 transmission and the potential for serious adverse reactions in breast-feeding infants, mothers should be instructed not to breast-feed if they are receiving Delstrigo.
Zaradi možnosti prenosa HIV-1 z matere na otroka in zaradi potencialno nevarnih neželenih učinkov pri dojenih otrocih je treba matere podučiti, naj ne dojijo, če prejemajo zdravilo Delstrigo.
At baseline, the median age of subjects was 43 years, 16 % were female, and 24 % were nonwhite.
Izhodiščno je bila mediana starost preiskovancev 43 let, 16 % je bilo žensk in 24 % preiskovancev ni bilo belcev.
Miscellaneous sorbitol solution (3.2 g, 10.2 g, 13.4 g)/lamivudine
Razno raztopina sorbitola (3,2 g, 10,2 g, 13,4 g)/lamivudin
There is not sufficient clinical evidence to support the use of doravirine in patients infected with HIV-1 with evidence of resistance to the NNRTI class.
Ni zadostnih kliničnih dokazov za podporo uporabi doravirina pri bolnikih, okuženih z virusom HIV-1, ki imajo dokazano odpornost proti NNRTI.
Of the 7 subjects who developed high level doravirine resistance in the pivotal studies, 6 had phenotypic resistance to EFV and nevirapine, 3 to rilpivirine, and 2 had partial resistance to etravirine based on the Monogram Phenosense assay.
Od 7 preiskovancev, ki se jim je v ključnih študijah pojavila visoka raven odpornosti proti doravirinu, jih je 6 imelo fenotipsko odpornost proti efavirenzu in nevirapinu, 3 proti rilpivirinu, 2 pa sta imela na podlagi preizkusa Monogram Phenosense delno odpornost proti etravirinu.
Delstrigo is used to treat HIV (‘human immunodeficiency virus') infection.
Zdravilo Delstrigo se uporablja za zdravljenje okužbe z virusom HIV (virusom humane imunske pomanjkljivosti).
Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breast-fed infants of mothers treated for HIV are very low (< 4 % of maternal serum concentrations) and progressively decrease to undetectable levels when breast-fed infants reach 24 weeks of age.
Določitev pri več kot 200 parih mater in otrok, zdravljenih zaradi HIV, je pokazala, da je koncentracija lamivudina v serumu dojenih dojenčkov mater, zdravljenih zaradi HIV, zelo majhna (manj kot 4 % koncentracije v materinem serumu) in se progresivno zmanjša do nezaznavne ravni, ko dojenček doseže 24 tednov starosti.
Tenofovir diphosphate inhibits the activity of HIV-1 RT by competing with the natural substrate deoxyadenosine 5´-triphosphate and, after incorporation into DNA, by DNA chain termination.
Tenofovirdifosfat zavira aktivnost RT HIV-1 s tekmovanjem z naravnim substratom deoksiadenozin 5'-trifosfatom in - po vključitvi v DNA - z zaključitvijo verige DNA.
Administration of doravirine in animal toxicity studies was not associated with toxicity.
Doravirin Uporaba doravirina v študijah toksičnosti na živalih ni bila povezana s toksičnimi učinki.
NNRTI-associated mutations detected at screening were part of exclusion criteria in the Phase 2b/3-studies.
Z NNRTI povezane mutacije, ugotovljene ob presejanju, so bile v študijah faz 2b/3 eno od meril za nevključitev.
Talk with your doctor about the best way to feed your baby.
O najustreznejšem načinu hranjenja otroka se posvetujte z zdravnikom.
• muscle symptoms (pain, stiffness)
• mišični simptomi (bolečine, togost)
Special care is advised in this age group due to age associated changes such as decreases in renal function (see section 4.4).
Posebna previdnost je v tej starostni skupini potrebna zaradi starostnih sprememb, npr. zmanjšanega delovanja ledvic (glejte poglavje 4.4).
The DRIVE-SHIFT study included virologically suppressed patients (N=670) with no history of treatment failure (see section, Clinical experience).
V študiji DRIVE-SHIFT so bili vključeni virološko suprimirani bolniki (N = 670), ki v anamnezi niso imeli neuspeha zdravljenja (glejte naslednje poglavje, Klinične izkušnje).
Delstrigo contains the active substances:
Zdravilo Delstrigo vsebuje naslednje učinkovine:
If you have both HIV and hepatitis B virus infections, your hepatitis B may get worse if you stop taking Delstrigo.
Če ste okuženi z virusom HIV in virusom hepatitisa B, se vam hepatitis B lahko poslabša, če nehate jemati zdravilo Delstrigo.
If you take more Delstrigo than you should Do not take more than the recommended dose.
Če ste vzeli večji odmerek zdravila Delstrigo, kot bi smeli Ne vzemite odmerka, večjega od priporočenega.
Safety and efficacy of Delstrigo have not been established in patients younger than 18 years of age.
Varnost in učinkovitost zdravila Delstrigo pri bolnikih, mlajših od 18 let, nista bili dokazani.
Approximately 71 % of an intravenous dose of lamivudine is recovered as unchanged medicinal product in the urine.
Približno 71 % intravenskega odmerka lamivudina se izloči z urinom kot nespremenjeno zdravilo.
Based on the results of in vitro experiments and the known elimination pathway of tenofovir, the potential for CYP-mediated interactions involving tenofovir with other medicinal products is low.
Glede na rezultate poskusov in vitro in znane poti odstranjevanja tenofovirja je možnost za medsebojna delovanja tenofovirja in drugih zdravil preko CYP majhna.
The following de novo resistance was seen in the resistance analysis subset (subjects with HIV-1 RNA greater than 400 copies per mL at virologic failure or at early study discontinuation and having resistance data).
Naslednjo de novo odpornost so ugotovili v podskupini za analizo odpornosti (preiskovanci, ki so imeli HIV-1 RNA več kot 400 kopij/ml ob virološkem neuspehu ali zgodnjem prenehanju sodelovanja v študiji ter so zanje imeli podatke o odpornosti).
At baseline, the median age of subjects was 33 years (range 18 to 69 years), 86 % had CD4
V izhodišču je bila mediana starost preiskovancev 33 let (razpon: od 18 do 69 let), 86 % jih je imelo število celic T CD4
Endothelin Receptor Antagonists bosentan
Antagonisti endotelinskih receptorjev bosentan
What Delstrigo is and what it is used for
Kaj je zdravilo Delstrigo in za kaj ga uporabljamo
The principal mode of action of 3TC-TP is inhibition of RT via DNA chain termination after incorporation of the nucleotide analogue.
Glavni način delovanja 3TC-TP je zavrtje RT z zaključitvijo verige DNA po vgradnji nukleotidnega analoga.